Endometriosis

Myovant Sciences and Evidation Announce Survey Results of Unseen Burdens at Work and School of Individuals with Endometriosis and/or Uterine Fibroids

Retrieved on: 
Wednesday, May 17, 2023
Wearables, Mobile Technology, Technology, Women, Health Technology, Software, Consumer, Health, Data Management, Science, Other Science, Endometriosis, Pelvic inflammatory disease, Life, Education, Workplace, Absenteeism, Dysmenorrhea, Statistics, Innovation, Multimedia, Cycle, Interface (computing), Meigs's syndrome, Roivant Sciences, Uterine fibroid, Fibroid, Menstrual cycle, Diagnosis, Entrepreneurship, Ageing, Uterine cancer, Primary ovarian insufficiency, Ovarian cancer, Environment, Female, Nursing, Management, Medical device, Medical imaging, Birth control, Evidence-based policy

Today, as part of National Women’s Health Week, Evidation and Myovant Sciences Ltd. (“Myovant”), a wholly owned subsidiary of Sumitovant Biopharma Ltd. (“Sumitovant”) announced results from a survey exploring the lived experiences of individuals with endometriosis and/or uterine fibroids.

Key Points: 
  • Today, as part of National Women’s Health Week, Evidation and Myovant Sciences Ltd. (“Myovant”), a wholly owned subsidiary of Sumitovant Biopharma Ltd. (“Sumitovant”) announced results from a survey exploring the lived experiences of individuals with endometriosis and/or uterine fibroids.
  • View the full release here: https://www.businesswire.com/news/home/20230517005194/en/
    “At Myovant, we know that stigma can often keep people quiet about periods, leading to delayed care and increased discomfort.
  • It also contributes to the lack of awareness about how conditions such as endometriosis and uterine fibroids can increase absenteeism and impact performance at work and school,” said Kalahn Taylor-Clark, vice president and head of Strategic Partnerships and Innovation at Myovant Sciences.
  • The survey covered four areas, including demographics, menstrual history and health, experiences at work or school, and experiences with medical providers.

EDAP Announces First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 17, 2023
Endometriosis, AUC, Prostate cancer, AUA, EDAP, Quality of life, EDT, MRI, Patient, Urology, Growth, Endo, EAU, Safety, Pharmaceutical industry

- Company to host conference call and webcast today, Wednesday, May 17that 8:30 am EDT -

Key Points: 
  • - Company to host conference call and webcast today, Wednesday, May 17that 8:30 am EDT -
    LYON, France, May 17, 2023 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today unaudited financial results for the first quarter ended March 31, 2023.
  • “After achieving record results in the fourth quarter of 2022, we continued to see growing demand through the first quarter of 2023, with our strongest Q1 revenue performance on record,” said Ryan Rhodes, Chief Executive Officer of EDAP.
  • The increase was driven by six Focal One units sold in the first quarter 2023 versus four units sold in the first quarter 2022.
  • A conference call and webcast to discuss first quarter 2023 financial results will be hosted by Ryan Rhodes, Chief Executive Officer, François Dietsch, Chief Financial Officer and Ken Mobeck, Chief Financial Officer of the U.S. subsidiary, today Wednesday, May 17th, 2023 at 8:30am EDT.

Celmatix Appoints Drug Development Expert Dr. Susan Herbert to Strategic Advisory Board

Retrieved on: 
Tuesday, May 16, 2023
Biotechnology, Pharmaceutical, Health, Other Health, Endometriosis, Business development, Venture, Drug development, Central Waqf Council, University, Senior, Doctor of Philosophy, Merck Group, Merck Serono, Biopharma LLC, Business, Woman, Advisory board, Federal Executive Boards, Inc., PCOS, Master of Science, Medicine, Corporation, United Kingdom, Knowledge, Growth, Merck, Pharmaceutical industry, Biochemistry

Celmatix Inc the leading women’s health biotech focused uniquely on ovarian biology, today announced that Dr. Susan Herbert has joined the company’s board of advisors.

Key Points: 
  • Celmatix Inc the leading women’s health biotech focused uniquely on ovarian biology, today announced that Dr. Susan Herbert has joined the company’s board of advisors.
  • Dr. Herbert brings more than 30 years of biopharma industry experience within R&D, business development and Corporate strategy along with unique insights gained heading the investment committee of MVentures.
  • Dr. Piraye Yurttas Beim, Celmatix Founder and CEO commented, “We are honored to have someone with Dr. Herbert’s experience and success in biopharma join our Strategic Advisory Board.
  • There has never been more at stake for women’s health and we are at the cusp of a new era in drug development.

Aspira Women’s Health to Host Investor Day on OvaWatch(SM) and EndoCheck™ Market Opportunities on May 23, 2023

Retrieved on: 
Monday, May 15, 2023
Endometriosis, Brigham and Women's Hospital, Woman, FACOG, Reproductive biology, Assistant, Gynaecology, Harvard Medical School, Education minister, Diagnosis, Hospital, Ovarian cancer, Medical device, Obstetrics

AUSTIN, Texas, May 15, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it will host a virtual Investor Day on Tuesday, May 23, 2023 at 1:00pm ET.

Key Points: 
  • AUSTIN, Texas, May 15, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it will host a virtual Investor Day on Tuesday, May 23, 2023 at 1:00pm ET.
  • The event will be hosted by Nicole Sandford, President and CEO, Dr. Ryan Phan, Chief Scientific and Operating Officer, and Dr. Charles Dunton, Chair of Aspira’s Scientific Advisory Board.
  • Dr. Tamika Sea, FACOG, obstetrician, gynecologist and Founder/Owner of Advanced Women’s Care Center in Atlanta, Georgia.
  • The program will also discuss the expansion of Aspira’s OvaWatch test for serial monitoring to enhance clinical management of adnexal masses.

Aspira Women’s Health Signs an Exclusive Licensing Agreement with Dana Farber Cancer Institute for the Development of microRNA-based Ovarian Cancer Test

Retrieved on: 
Thursday, May 11, 2023
Endometriosis, DFCI, Radiation, Survival, Risk assessment, Woman, MicroRNA, Research, RNA, Gynaecology, Dana–Farber Cancer Institute, Protein, Division, Physician, Risk, Aspira, Algorithm, Blood, Cell nucleus, Ovarian cancer, Pharmaceutical industry, Medical imaging

AUSTIN, Texas, May 11, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today announced it has signed an exclusive licensing agreement with the Dana-Farber Cancer Institute (“DFCI”) for the design and development of a new noninvasive miRNA-based ovarian cancer diagnostic tool.

Key Points: 
  • AUSTIN, Texas, May 11, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today announced it has signed an exclusive licensing agreement with the Dana-Farber Cancer Institute (“DFCI”) for the design and development of a new noninvasive miRNA-based ovarian cancer diagnostic tool.
  • The new test will utilize circulating microRNAs, either alone or in conjunction with proteins or other factors, to identify ovarian cancer in women with adnexal masses.
  • It will be offered to healthcare providers as an expansion of the Company’s OvaSuite porfolio.
  • “Diagnosing ovarian cancer at its earliest stages is crucial to improving survival outcomes,” said Dr. Ryan Phan, Aspira’s Chief Scientific and Operating Officer.

Northwell Health Commits $1M to Fund Employee Ideas for Healthcare Innovation During Big Ideas Showcase

Retrieved on: 
Monday, May 8, 2023
Hospitals, General Health, Health, Oncology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Endometriosis, Hofstra University, Donald, Brain, LAUNCH (Innovation Challenge), Culture, Feinstein Institutes for Medical Research, Stroke, DRS, Innovation, MBA, Research, Multimedia, Doctor of Philosophy, Science, Creativity, Trigeminal nerve, North Shore University Hospital, National Institute of Neurological Disorders and Stroke, Neurosurgery, Patient, Nature, HPV, Neurology, Navigation, White, Human papillomavirus infection, Medical research, Nursing, Pharmaceutical industry, Management, Medical imaging, Medical device, Northwell Health, Cancer, MD

Northwell Health has awarded $1 million toward the research and development of two employee-driven projects that drive the goal of transforming the future of health care with new ideas during the health system’s 2023 Innovation Challenge.

Key Points: 
  • Northwell Health has awarded $1 million toward the research and development of two employee-driven projects that drive the goal of transforming the future of health care with new ideas during the health system’s 2023 Innovation Challenge.
  • Winners of the competition included team leads hailing from the Feinstein Institutes for Medical Research , the home of research at Northwell Health.
  • The announcement was made during the health system’s Made for Big Ideas™ Showcase.
  • To date, Northwell has awarded funding for 13 projects to advance their progress and develop their innovative ideas.

Ironwood Pharmaceuticals Reports First Quarter 2023 Results; Maintains Full Year 2023 Financial Guidance

Retrieved on: 
Thursday, May 4, 2023
Research, Clinical Trials, Biometrics, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Endometriosis, Income tax, Senior, Interest, Test Claimants in the Franked Investment Income Group Litigation v IRC, PBC, New Drug Application, Constipation, GAAP, Functional constipation, Trial of the century, IC/BPS, Interstitial cystitis, Primary biliary cholangitis, Shanda, EBITDA, Patient, AbbVie, Autoimmune disease, PDUFA, Liver, Depreciation, Ageing, Phase, FDA, Total, Safety, Pharmaceutical industry, Video game, Bookkeeping, Security (finance), Reinsurance, Ironwood

On April 10, 2023, Ironwood determined to eliminate the role of chief operating officer to streamline the executive leadership team.

Key Points: 
  • On April 10, 2023, Ironwood determined to eliminate the role of chief operating officer to streamline the executive leadership team.
  • Total revenues in the first quarter of 2023 were $104.1 million, compared to $97.5 million in the first quarter of 2022.
  • Operating expenses in the first quarter of 2023 were $44.0 million, compared to $39.7 million in the first quarter of 2022.
  • – Ironwood generated $80.2 million in cash from operations in the first quarter of 2023, compared to $64.1 million in cash from operations in the first quarter of 2022.

CCRM Fertility Adds Dr. Sina Abhari to its Orange County Physician Team

Retrieved on: 
Wednesday, May 3, 2023
Emory University, Endometriosis, Avicenna International College, Infertility, Ovarian reserve, Research, Fertilisation, Gynaecology, Reproductive biology, Science, Suite, Fertility, American Society for Reproductive Medicine, Publication, Johns Hopkins University, Patient, Physician, Uterine fibroid, Michigan State University, Obstetrics, ASRM, Reproductive medicine, Health, Society, Birth control, Endocrinology

NEWPORT BEACH, Calif., May 3, 2023 /PRNewswire/ -- CCRM Fertility, the global pioneer in fertility treatment, research and science, welcomes Dr. Sina Abhari to its team of physicians in Newport Beach, Calif. Dr. Abhari is a reproductive endocrinology and infertility specialist who is board-certified in obstetrics and gynecology and board-eligible in reproductive endocrinology and infertility. He joins CCRM Fertility as medical director after coming from Johns Hopkins University as an assistant professor and specialist in reproductive endocrinology and infertility. Dr. Abhari is currently accepting new patients.

Key Points: 
  • He joins CCRM Fertility as medical director after coming from Johns Hopkins University as an assistant professor and specialist in reproductive endocrinology and infertility.
  • "There is an increasing need for high-quality fertility treatments, with approximately one in six people experiencing infertility at some stage in their lives," said CCRM Fertility CEO Bob LaGalia.
  • "With the addition of Dr. Abhari to our Orange County team, we can help even more individuals and couples grow their families with compassionate and innovative fertility care."
  • CCRM Fertility of Orange County is located at: 3501 Jamboree, Suite 1100, Newport Beach, CA 92660.

Curve Biosciences Appoints Industry Veterans to Leadership Team, Announces Commercial Advisory Board

Retrieved on: 
Wednesday, May 3, 2023
Health, Technology, Other Health, Software, General Health, Research, Science, Acumen, Insurance, Communication, CDTA, Aetna, Marketing, Stanford University, Longevity, Doctor of Philosophy, GRAIL, Genetics, MD, Patient, Conditional sentence, Commercial Operating System, San Francisco, Tissue, University, CSO, Inflammatory bowel disease, Burns, DaVita Inc., Medicine, Chronic condition, Biology, Liver, Cancer, Electrical engineering, Data mining, Biomarker, CVS Health, Chronic liver disease, UnitedHealth Group, Electricity, Endometriosis, University of California, San Francisco, Human Longevity, Genomics, Trial of the century, Biological engineering, World Health Organization, Management, Medical imaging, Pharmaceutical industry, Myriad Genetics, Natera, Curve

“Chuba and Nathan have created, launched, and scaled multiple products, including in early disease detection,” said Ritish Patnaik, PhD , CEO of Curve.

Key Points: 
  • “Chuba and Nathan have created, launched, and scaled multiple products, including in early disease detection,” said Ritish Patnaik, PhD , CEO of Curve.
  • She previously was vice president of Commercial Operations at Counsyl, and held leadership roles at DaVita and MyHealthTeam.
  • He previously held the same role at Serimmune, Inc., and held commercial leadership roles at Human Longevity, Counsyl, AltheaDx and Verinata.
  • We look forward to working with our advisors to maintain our progress and explore commercial opportunities in other chronic diseases.”

Why menstrual leave could be bad for women

Retrieved on: 
Friday, April 28, 2023
Endometriosis, Depression, Life, Friends, Workplace, Leadership, Parent, Policy, Premenstrual dysphoric disorder, Woman, Parental leave, Polycystic ovary syndrome, School, Human, Outline, Stigma, Menstruation, Child, Comment, Quarterlife, Menstrual cycle, Diagnosis, Fibroid, Health, Mental health, Family, Sick leave, Female, Birth control, Toy, Nursing, EU

Spain recently adopted a menstrual leave policy, which makes additional (paid or unpaid) days off work available to “only and all cisgender women”.

Key Points: 
  • Spain recently adopted a menstrual leave policy, which makes additional (paid or unpaid) days off work available to “only and all cisgender women”.
  • It’s so great that we’re having more public conversations about menstrual and menopausal health, but I’m getting very tired of being told that menstrual leave is the solution.

What is the problem?


    There are four main arguments used by those promoting menstrual leave policy:
    • In fact, based on what we know about existing menstrual leave policies, it might not contribute to any of them.
    • This article is part of Quarter Life, a series about issues affecting those of us in our twenties and thirties.
    • Encouraging people to cope with severe symptoms alone at home every month, is not an effective or humane solution.
    • The same things that apply to all chronic health conditions and are already covered by EU and UK labour policies.

Menstrual leave might even make things worse

    • Not only have existing menstrual leave policies failed to address the problems they set out to solve, they have also directly resulted in discrimination against female workers.
    • It can also lead to a backlash from colleagues and employers against a sex-based benefit.
    • We already know that shared parental leave (for parents regardless of gender) is a more effective policy than maternity leave (which is female sex-based).
    • These improvements occur because the policy avoids the gender-based backlash associated with maternity leave.